Loading...
 
Toggle Health Problems and D

Fight infections such as COVID with 50 ng of Vitamin D – Sunil Dec 2022

Overcoming Infections Including COVID-19, by Maintaining Circulating 25(OH)D Concentrations Above 50 ng/mL

Pathology and Laboratory Medicine Int. Vol 14 Pages 37—60, DOI https://doi.org/10.2147/PLMI.S373617
Sunil J Wimalawansa suniljw at hotmail.com
Department of Medicine, CardioMetabolic and Endocrine Institute, North Brunswick, NJ, USA

Image

Image

Image

Half of the people get to 50 ng with 5,000 IU daily
Image
Note: Virtually all get to 40 ng with 7,000 IU daily (50,000 IU weekly)

The elderly and those with underlying chronic diseases (i.e., comorbidities) such as pulmonary, cardiovascular, metabolic, and renal diseases, increase their susceptibility to sepsis, including COVID-19. The SARS-CoV-2 virus damages pulmonary cells, causing acute respiratory distress syndrome (ARDS) and hypoxia. It further damages endothelial cells, altering clotting mechanisums causing intravascular hemolysis, microvascular thrombosis, and micro-embolization, contributing to the risk of death.
Approximately 75% of the immune system functions of humans depend on vitamin D and the availability of sufficient amounts of vitamin D metabolites [vitamin D and 25(OH)D] concentrations to enter immune cells from the bloodstream. Such concentrations are achievable through sun exposure, targeted food fortification programs, and adequate daily or weekly vitamin D supplements. That would allow for generating 1,25(OH)2D (non-hormonal form of calcitriol) intracellularly in peripheral target cells like immune cells. This enables immune cells’ physiological functions, including intracrine/autocrine and paracrine signaling processes. This initiates and maintains robust immune functions, such as forming antibodies and antimicrobial peptides, suppressing inflammation, and increasing the expression of anti-inflammatory and antioxidant genes, thus, strengthening immune functions. The opposite occurs in hypovitaminosis D, increasing vulnerability to infections and dying from it. Therefore, governments should make the population sufficient with immunoceuticals—micronutrients, especially vitamin D, and other micronutrients: the most cost-effective intervention to keep the population healthy. The cost of such interventions are minuscule compared to the expenses related to increased hospitalizations and premature deaths. Supposed such a program was implemented in mid-2020 as the author proposed, we estimated that 50% of hospitalizations (and the associated healthcare costs) and a third of deaths from COVID could have been prevented. Described herein are cost-effective strategies using vitamin D to achieve and sustain serum D3 and 25(OH)D concentrations crucial for maintaining a robust immune system, improving general health, minimizing disease severities and deaths, and reducing healthcare costs.

Why is It Necessary to Target Serum 25(OH)D Concentration Above 50 ng/mL?

Good public health policies aim to minimize diseases, their complications, and the spread, cost-effectively. However, during the COVID pandemic, some of these principles were ignored by leading health authorities and governments, which led to chaos. Those who develop symptomatic disease and complications and die from infections have feeble immune systems. Therefore, maintaining a robust immune system is not only essential to protect the population during infectious pandemics like SARS-CoV-2 but also the most cost-effective way to control it.
Convincing evidence has been published that rapidly raising and maintaining vitamin D and/or serum 25(OH)D concentrations above the minimum required level of 50 ng/mL (125 nmol/L) would minimize infections-related adverse clinical outcomes.46-48 Therefore, in such situations, in addition to preventing disease spread (eg, wearing effective face masks and social distancing), a broader goal should be to maintain mentioned circulatory 25(OH)D concentration in the population that would significantly improve clinical outcomes, including fewer hospitalizations and deaths, while mimizing healthcare costs.50
If the goal is to achieve a population minimum serum 25(OH)D concentration of “40” ng/mL, 60% of people will be below the required serum 25(OH)D concentration of 50 ng/mL. Whereas, if the targeted minimum concentration is set for 30 ng/mL, more than 80% of the population will have serum 25(OH)D concentration below 50 ng/mL, due to the scatter of representation in the community. Consequently, such approaches are ineffective and unwise especially during infectious epidemics and pandemics. It would fail to maintain a robust immunity in the population that needs to overcome infections. This is a crucial reason for the community spread of SARS-CoV-2, its, severe complications and deaths from the current COVID pandemic.
Therefore, keeping individuals or the populations’ serum 25(OH)D concentration below 50 ng/mL as recommended by some as the lower limit, is unwise and undesirable.48 During infectious epidemics or pandemics, there is no scientific justification for maintaining minimum serum 25(OH)D concentrations at 20, 30, or even 40 ng/mL, suggested as precautionary (and theoretical) principles by some. It would lead to serum 25(OH)D concentration of over two thirds of the population under the minimum necessary level of 50 ng/mL—disadvantage them by contracting infectious pathogens—both bacteria and viruses—therefore, it is counterproductive. Such a policy would enhance the spread of the viral illness, increase complications, hospitalizations, deaths, and associated costs.
 Download the PDF from VitaminDWiki

VitaminDWiki - Is 50 ng of vitamin D too high, just right, or not enough

which contains

Vitamin D Treats
150 ng Multiple Sclerosis *
80 ng Cluster Headache *
Reduced office visits by 4X *
70 ngSleep *
60 ngBreast Cancer death reduced 60%
Preeclampsia RCT
50 ng COVID-19
T1 Diabetes
Fertility
Psoriasis
Infections Review
Infection after surgery
40 ng Breast Cancer 65% lower risk
Depression
ACL recovery
Hypertension
Asthma?
30 ng Rickets

* Evolution of experiments with patients, often also need co-factors

VitaminDWiki - Diseases treated by high-dose Vitamin D - many studies

116,000 fewer IS COVID Death if everyone had been taking 50,000 IU Vitamin D - VA Nov 2022

VitaminDWiki - COVID-19 treated by Vitamin D - studies, reports, videos

82+ pages have 50 ng in VitaminDWiki title

This list is automatically updated

References

  1. Wimalawansa SJ. Global epidemic of coronavirus—COVID-19: what can we do to minimize risks? European J. Biomed Pharma Sci. 2020;7 (3) :432-438.
  2. Wang L, Berger NA, Kaelber DC, et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv. 2022. doi:10.1101/2021.12.30.21268495
  3. Qi ZH, Bei ZF, Teng S, et al. Clinical features of 19 children infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 in Hangzhou. China Zhongguo Dang Dai Er Ke Za Zhi. 2022;24(10):1092-1097.
  4. Wang X, Chang H, Tian H, et al. Epidemiological and clinical features of SARS-CoV-2 infection in children during the outbreak of Omicron variant in Shanghai, March 7- 31,2022. Influenza Other Respir Viruses. 2022;16(6):1059-1065. doi:10.1111/irv. 13044
  5. Suryawanshi RK, Chen IP, Ma T, et al. Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination. medRxiv. 2022. doi:10.1101/2022.01.13.22269243
  6. Ledford H. How severe are Omicron infections? Nature. 2021;600(7890):577-578. doi:10.1038/d41586-021-03794-8
  7. Torjesen I. Covid-19: omicron variant is linked to steep rise in hospital admissions of very young children. BMJ. 2022;376:o110. doi:10.1136/bmj.o110
  8. Chen KK, Huang DT, Huang LM. SARS-CoV-2 variants - evolution, Spike protein, and vaccines. Biomed J. 2022;45:573-579. doi:10.1016/j. bj.2022.04.006
  9. Shrestha LB, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol. 2022;32(5):e2381. doi:10.1002/rmv.2381
  10. Zhou H, Dcosta BM, Landau NR, et al. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to vaccine-elicited sera and therapeutic monoclonal antibodies. Viruses. 2022;14(6):1334. doi:10.3390/v14061334
  11. Armitage R, Nellums LB. COVID-19 and the consequences of isolating the elderly. Lancet Public Health. 2020;5(5):e256. doi:10.1016/S2468- 2667(20)30061-X
  12. Reyes-Ortiz CA, Williams C, Westphal C. Comparison of early versus late palliative care consultation in end-of-life care for the hospitalized frail elderly patients. Am J Hosp Palliat Care. 2015;32(5):516-520. doi:10.1177/1049909114530183
  13. SeyedAlinaghi S, Mehrtak M, MohsseniPour M, et al. Genetic susceptibility of COVID-19: a systematic review of current evidence. Eur J Med Res. 2021;26(1):46. doi:10.1186/s40001-021-00516-8
  14. Barrea LV, Grant L, Frias-Toral WB, et al. Vitamin D: a role also in long COVID-19? Nutrients. 2022;14:1625. doi:10.3390/nu14081625
  15. Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21(1):148. doi:10.1186/s12933-022-01579-5
  16. Thapa Magar S, Lokhandwala HI, Batool S, et al. A Systematic Review of neurological manifestations of COVID-19. Cureus. 2022;14(8): e28309. doi:10.7759/cureus.28309
  17. Sanabria-Diaz G, Etter MM, Melie-Garcia L, et al. Brain cortical alterations in COVID-19 patients with neurological symptoms. Front Neurosci. 2022;16:992165. doi:10.3389/fnins.2022.992165
  18. Boucher BJ. Vitamin D deficiency in British South Asians, a persistent but avoidable problem associated with many health risks (including rickets, T2DM, CVD, COVID-19 and pregnancy complications): the case for correcting this deficiency. Endocr Connect. 2022;11(12). doi:10.1530/EC-22-0234
  19. GAO-21-319. Operation warp speed: accelerated COVID-19 vaccine development status and efforts to address manufacturing challenges. Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing Challenges. U.S. GAO; 2020. Available from: www.gao.gov/products/gao-21-319. Accessed November 29, 2022.
  20. Wolfl-Duchek M, Bergmann F, Jorda A, et al. Sensitivity and specificity of SARS-CoV-2 rapid antigen detection tests using oral, anterior nasal, and nasopharyngeal swabs: a diagnostic accuracy study. Microbiol Spectr. 2022;10(1):e0202921. doi:10.1128/spectrum.02029-21
  21. Zhan Z, Li J, Cheng ZJ. Rapid antigen test combine with nucleic acid detection: a better strategy for COVID-19 screening at points of entry. J Epidemiol Glob Health. 2022;12(1):13-15. doi:10.1007/s44197-021-00030-4
  22. Islamoska S, Petersen JH, Benfield T, et al. Socioeconomic and demographic risk factors in COVID-19 hospitalization among immigrants and ethnic minorities. Eur J Public Health. 2022;32(2):302-310. doi:10.1093/eurpub/ckab186
  23. Aldridge RW, Lewer D, Katikireddi SV, et al. Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. Wellcome Open Res. 2020;5:88. doi:10.12688/wellcomeopenres.15922.2
  24. Holmes L, Enwere M, Williams J, et al. Black-white risk differentials in COVID-19 (SARS-COV2) transmission, mortality and case fatality in the United States: translational epidemiologic perspective and Challenges. Int J Environ Res Public Health. 2020;17(12):4322. doi:10.3390/ ijerph17124322
  25. Roizen JD, Long C, Casella A, et al. Obesity decreases hepatic 25-hydroxylase activity causing low serum 25-hydroxyvitamin D. J Bone Miner Res. 2019;34(6):1068-1073. doi:10.1002/jbmr.3686
  26. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690-693. doi:10.1093/ ajcn/72.3.690
  27. Walsh JB, McCartney DM, Laird É, et al. Understanding a low vitamin D state in the context of COVID-19. Front Pharmacol. 2022;13:835480. doi:10.3389/fphar.2022.835480
  28. Phommasone K, Xaiyaphet X, Garcia-Rivera JA, et al. A case-control study of the causes of acute respiratory infection among hospitalized patients in Northeastern Laos. Sci Rep. 2022;12(1):939. doi:10.1038/s41598-022-04816-9
  29. Ekwaru JP, Zwicker JD, Holick MF, et al. The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLoS One. 2014;9(11):e111265. doi:10.1371/journal.pone.0111265
  30. Wimalawansa SJ. Biology of Vitamin D. J Steroids Horm Sci. 2019;198(1):1-8.
  31. Vieth R. Vitamin D supplementation: cholecalciferol, calcifediol, and calcitriol. Eur J Clin Nutr. 2020;74(11):1493-1497. doi:10.1038/s41430- 020-0697-1
  32. Tieu S, Charchoglyan A, Lauri Wagter-Lesperance LW, et al. Immunoceuticals: harnessing their immunomodulatory potential to promote health and wellness. Nutrients. 2022;14:4075. doi:10.3390/nu14194075
  33. Pludowski P, Holick MF, Grant WB, et al. Vitamin D supplementation guidelines. J SteroidBiochem Mol Biol. 2018;175:125-135. doi:10.1016/ j.jsbmb.2017.01.021
  34. McCartney DM, Byrne DG. Optimisation of vitamin D status for enhanced immuno-protection against COVID-19. Ir Med J. 2020;113(4):58.
  35. Zhou YF, Luo BA, Qin LL. The association between vitamin D deficiency and community-acquired pneumonia: a meta-analysis of observational studies. Medicine. 2019;98(38):e17252. doi:10.1097/MD.0000000000017252
  36. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health. 2020;13(10):1373-1380. doi:10.1016/j.jiph.2020.06.021
  37. Borsche L, Glauner B, von Mendel J. COVID-19 mortality risk correlates inversely with vitamin D3 Status, and a mortality rate close to zero could theoretically be achieved at 50 ng/mL 25(OH)D3: results of a systematic review and meta-analysis. Nutrients. 2021;13(10):3596. doi:10.3390/nu13103596
  38. Luxwolda MF, et al., Vitamin D status indicators in indigenous populations in East Africa. Eur J Nutr, 2013. 52(3): p. 1115-25.
  39. Luxwolda MF, Kema KR, IP JDBD, Muskiet FA, Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. Br J Nutr., 2012: p. 1-5
  40. Gibbons JB, et al., Association between vitamin D supplementation and COVID-19 infection and mortality. Sci Rep, 2022. 12(1): p. 193
  41. Jayawardena R, Jeyakumar DT, Francis TV, et al. Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries. Diabetes Metab Syndr. 2021;15(3):757-764. doi:10.1016/j.dsx.2021.03.006
  42. Castillo EM, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203:105751. doi:10.1016/j.jsbmb.2020.105751
  43. Wimalawansa SJ, Polonowita A Boosting immunity with vitamin D for preventing complications and deaths from COVID-19. in COVID 19: impact, mitigation, opportunities and building resilience “From adversity to serendipity”, perspectives of global relevance based on research, experience and successes in combating COVID-19 in Sri Lanka. Colombo, Sri Lanka: National Science Foundation, Sri Lanka; 2021.
  44. Quraishi SA, Litonjua AA, Moromizato T, et al. Association between prehospital vitamin D status and hospital-acquired bloodstream infections. Am J Clin Nutr. 2013;98(4):952-959. doi:10.3945/ajcn.113.058909
  45. Carter SJ, Baranauskas MN, Fly AD. Considerations for obesity, vitamin D, and physical activity amidst the COVID-19 pandemic. Obesity. 2020;28:1176-1177. doi:10.1002/oby.22838
  46. DrorI A, MorozovI N, Daoud A, et al. Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness. PLoS One. 2022;17:1-18.
  47. Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-A systematic review of current evidence. Ecancermedical Sci. 2020;14:1022. doi:10.3332/ecancer.2020.1022
  48. Bishop E, Ismailova A, Dimeloe S, et al. Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory. JBMR Plus. 2020;5:e10405.
  49. Cao Z, Wu Y, Faucon E, et al. SARS-CoV-2 & Covid-19: key-roles of the ‘renin-angiotensin’ system/ vitamin D impacting drug and vaccine developments. Infect Disord Drug Targets. 2020;20(3):348-349. doi:10.2174/1871526520999200505174704
  50. Czaja AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. World J Gastroenterol. 2016;22(42):9257-9278. doi:10.3748/wjg.v22.i42.9257
  51. Jin D, Wu S, Zhang Y-G, et al. Lack of vitamin D receptor causes dysbiosis and changes the functions of the murine intestinal microbiome. Clin Ther. 2015;37(5):996-1009 e7. doi:10.1016/j.clinthera.2015.04.004
  52. Laplana M, Royo JL, Fibla J. Vitamin D Receptor polymorphisms and risk of enveloped virus infection: a meta-analysis. Gene. 2018;678:384-394. doi:10.1016/j.gene.2018.08.017
  53. Platitsyna NG, Bolotnova TV. Vitamin D deficiency as a risk factor for chronic non-infectious diseases. Adv Gerontol. 2017;30(6):873-879.
  54. Pletz MW, Terkamp C, Schumacher U, et al. Vitamin D deficiency in community-acquired pneumonia: low levels of 1,25(OH)2 D are associated with disease severity. Respir Res. 2014;15:53. doi:10.1186/1465-9921-15-53
  55. Ginde AA, Mansbach JM, Camargo CA. Vitamin D, respiratory infections, and asthma. Curr Allergy Asthma Rep. 2009;9(1):81-87. doi:10.1007/s11882-009-0012-7
  56. Ianevski A, Zusinaite E, Shtaida N, et al. Low temperature and low UV indexes correlated with peaks of influenza virus activity in Northern Europe during 2010-2018. Viruses. 2019;11(3):207. doi:10.3390/v11030207
  57. Imai CM, Halldorsson TI, Eiriksdottir G, et al. Depression and serum 25-hydroxyvitamin D in older adults living at northern latitudes - AGES-Reykjavik Study. J Nutr Sci. 2015;4:e37. doi:10.1017/jns.2015.27
  58. Devaraj S, Jialal G, Cook T, et al. Low vitamin D levels in Northern American adults with the metabolic syndrome. Horm Metab Res. 2011;43 (1):72-74. doi:10.1055/s-0030-1268485
  59. Eroglu C, Demir F, Erge D, et al. The relation between serum vitamin D levels, viral infections and severity of attacks in children with recurrent wheezing. Allergol Immunopathol. 2019;47(6):591-597. doi:10.1016/j.aller.2019.05.002
  60. Arihiro S, Nakashima A, Matsuoka M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza and upper respiratory infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(6):1088-1095. doi:10.1093/ibd/izy346
  61. Jolliffe DA, Greiller CL, Mein CA, et al. Vitamin D receptor genotype influences risk of upper respiratory infection. Br J Nutr. 2018;120 (8):891-900. doi:10.1017/S000711451800209X
  62. Reichrath J, Saternus R, Vogt T. Challenge and perspective: the relevance of ultraviolet (UV) radiation and the vitamin D endocrine system (VDES) for psoriasis and other inflammatory skin diseases. Photochem Photobiol Sci. 2017;16(3):433-444. doi:10.1039/c6pp00280c
  63. Saraiva GL, Cendoroglo MS, Ramos LR, et al. Influence of ultraviolet radiation on the production of 25 hydroxyvitamin D in the elderly population in the city of Sao Paulo (23 degrees 34’S), Brazil. Osteoporos Int. 2005;16(12):1649-1654. doi:10.1007/s00198-005-1895-3
  64. Zdrenghea MT, Makrinioti H, Bagacean C, et al. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev Med Virol. 2017;27(1):e1909. doi:10.1002/rmv.1909
  65. Morris SK, Pell LG, Rahman MZ, et al. Maternal vitamin D supplementation during pregnancy and lactation to prevent acute respiratory infections in infancy in Dhaka, Bangladesh (MDARI trial): protocol for a prospective cohort study nested within a randomized controlled trial. BMC Pregnancy Childbirth. 2016;16(1):309. doi:10.1186/s12884-016-1103-9
  66. Sabatier I, Chabrier S, Brun A, et al. Stroke by carotid artery complete occlusion in Kawasaki disease: case report and review of literature. Pediatr Neurol. 2013;49(6):469-473. doi:10.1016/j.pediatmeurol.2013.08.011
  67. Di Filippo L, Allora A, Doga M, et al. Vitamin D levels are associated with blood glucose and BMI in COVID-19 patients, predicting disease severity. J Clin Endocrinol Metab. 2022;107(1):e348-e360. doi:10.1210/clinem/dgab599
  68. Di Filippo L, De Lorenzo R, Giustina A, et al. Vitamin D in osteosarcopenic obesity. Nutrients. 2022;14(9):1816. doi:10.3390/nu14091816
  69. Migliaccio S, Di Nisio A, Mele C, et al. Obesity and hypovitaminosis D: causality or casualty? Int J Obes Suppl. 2019;9(1):20-31. doi:10.1038/ s41367-019-0010-8
  70. Maddaloni E. Vitamin D and diabetes mellitus. Front Horm Res. 2018;50:161-176.
  71. Cashman KD, Ritz C, Carlin A, et al. Vitamin D biomarkers for Dietary Reference Intake development in children: a systematic review and meta-analysis. Am J Clin Nutr. 2022;115(2):544-558. doi:10.1093/ajcn/nqab357
  72. Cashman KD, FitzGerald AP, Viljakainen HT, et al. Estimation of the dietary requirement for vitamin D in healthy adolescent white girls. Am J Clin Nutr. 2011;93(3):549-555. doi:10.3945/ajcn.110.006577
  73. Merzon E, Tworowski D, Gorohovski A, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J. 2020;287(17):3693-3702. doi:10.1111/febs.15495
  74. Grant WB, Al Anouti F, Moukayed M. Targeted 25-hydroxyvitamin D concentration measurements and vitamin D3 supplementation can have important patient and public health benefits. Eur J Clin Nutr. 2020;74(3):366-376. doi:10.1038/s41430-020-0564-0
  75. Kazemi A, Mohammadi V, Aghababaee SA, Golzarand M, Clark CCT, Babajafari S. Association of vitamin D status with SARS-CoV-2 infection or COVID-19 severity: a systematic review and meta-analysis. Adv Nutr. 2021;00(p):1-23.
  76. Wimalawansa SJ. Controlling COVID-19 pandemic with cholecalciferol. Heathcare Res. 2020;5(1):155-165.
  77. Wimalawansa SJ. Oral calcifediol repletes blood vitamin D concentration within 4 hours; 2021. Available from: https://www.linkedin.com/ posts/sunilWimalawansa_oral-calcifediol-repletes-blood-vitamin-activity-6803351558714204160-dtnd. Accessed May 25, 2022.
  78. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311 (5768):1770-1773. doi:10.1126/science.1123933
  79. Vieth R. Why “Vitamin D” is not a hormone, and not a synonym for 1,25-dihydroxy-vitamin D, its analogs or deltanoids. J Steroid Biochem Mol Biol. 2004;89(1-5):571-573. doi:10.1016/j.jsbmb.2004.03.037
  80. Aygun H. Vitamin D can prevent COVID-19 infection-induced multiple organ damage. Naunyn Schmiedebergs Arch Pharmacol. 2020;393 (7):1157-1160. doi:10.1007/s00210-020-01911-4
  81. Kaufman HW, Niles JK, Kroll MH, et al. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS One. 2020;15(9):e0239252. doi:10.1371/journal.pone.0239252
  82. Alexander J, Tinkov A, Strand TA, et al. Early nutritional interventions with zinc, selenium and vitamin D for raising anti-viral resistance against progressive COVID-19. Nutrients. 2020;12(8):2358. doi:10.3390/nu12082358
  83. Bakaloudi DR, Chourdakis M. A critical update on the role of mild and serious vitamin D deficiency prevalence and the COVID-19 epidemic in Europe. Nutrition. 2022;93:111441. doi:10.1016/j.nut.2021.111441
  84. Akbari AR, Khan M, Adeboye W, et al. Ethnicity as a risk factor for vitamin D deficiency and undesirable COVID-19 outcomes. Rev Med Virol. 2021;32:e2291. doi:10.1002/rmv.2291
  85. Vanegas-Cedillo PE, Bello-Chavolla OY, Ramirez-Pedraza N, et al. Serum vitamin D levels are associated with Increased COVID-19 severity and mortality independent of whole-body and visceral adiposity. Front Nutr. 2022;9:813485. doi:10.3389/fnut.2022.813485
  86. DiNicolantonio JJ, O’Keefe JH. Magnesium and vitamin D deficiency as a potential cause of Immune dysfunction, cytokine storm and disseminated intravascular coagulation in COVID-19 patients. Mo Med. 2021;118(1):68-73. doi:10.1101/2020.04.24.20075838
  87. Kumar P, Kumar M, Bedi O, et al. Role of vitamins and minerals as immunity boosters in COVID-19. Inflammopharmacology. 2021;29 (4):1001-1016. doi:10.1007/s10787-021-00826-7
  88. Kumar R, Rathi H, Haq A, Wimalawansa SJ, Sharma A. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19. Virus Res. 2021;292:198235. doi:10.1016/j.virusres.2020.198235
  89. D’Avolio A, Avataneo V, Manca A, et al. 25-hydroxyvitamin D concentrations are Lower in patients with positive PCR for SARS-CoV-2. Nutrients. 2020;12(5):1359. doi:10.3390/nu12051359
  90. Sims JT, et al. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin Immunol 2020;147:107-111.
  91. Hojyo S, Uchida M, Tanaka K, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40:37. doi:10.1186/ s41232-020-00146-3
  92. Iannaccone G, Gul F, Ram P, et al. Weathering the cytokine storm in COVID-19: therapeutic implications. Cardiorenal Med. 2020;10:1-11. doi:10.1159/000503919
  93. Amaya-Mejia AS, O’Farrill-Romanillos PM, Galindo-Pacheco LV, et al. Vitamin D deficiency in patients with common variable immunodeficiency, with autoimmune diseases and bronchiectasis. Rev Alerg Mex. 2013;60(3):110-116.
  94. Broder AR, Tobin JN, Putterman C. Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison of three chronic diseases. Arthritis Res Ther. 2010;12(5):R191. doi:10.1186/ar3161
  95. Kurylowicz A, Bednarczuk T, Nauman J. The influence of vitamin D deficiency on cancers and autoimmune diseases development. Endokrynol Pol. 2007;58(2):140-152.
  96. Wimalawansa SJ. COVID-19: evolution and prevention. Trends Telemed E Health. 2020;2(3):1-5.
  97. Antal AS, Dombrowski Y, Koglin S, et al. Impact of vitamin D3 on cutaneous immunity and antimicrobial peptide expression. DermatoEndocrinol. 2011;3(1):18-22. doi:10.4161/derm.3.1.14616
  98. Gibson CC, Davis CT, Zhu W, et al. Dietary vitamin D and its metabolites non-genomically stabilize the endothelium. PLoS One. 2015;10(10): e0140370. doi:10.1371/journal.pone.0140370
  99. Aloia JF, Li-Ng M. Re: epidemic influenza and vitamin D. Epidemiol Infect. 2007;135(7):1095-1096. doi:10.1017/S0950268807008308
  100. Fleming DM, Elliot AJ. Epidemic influenza and vitamin D. Epidemiol Infect. 2007;135(7):1091-1092. doi:10.1017/S0950268807008291
  101. Moromizato T, Litonjua AA, Braun AB, et al. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill. Crit Care Med. 2014;42(1):97-107. doi:10.1097/CCM.0b013e31829eb7af
  102. Hanff TC, Harhay MO, Brown TS, et al. Is There an association between COVID-19 mortality and the renin-angiotensin system-a call for epidemiologic investigations. Clin Infect Dis. 2020;71:870-874. doi:10.1093/cid/ciaa329
  103. Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671-1681.
  104. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280. doi:10.1016/j.cell.2020.02.052
  105. Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75:1382-1385. doi:10.1161/HYPERTENSIONAHA.120.15082
  106. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3). doi:10.1093/jtm/taaa041
  107. Lim H, Kim SE, Lee YH, et al. Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein. Virology. 2022;573:118-123. doi:10.1016/j.virol.2022.06.006
  108. Almehdi AM, Khoder G, Alchakee AS, et al. SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. Infection. 2021;49 (4) :855-876. doi:10.1007/s15010-021-01677-8
  109. Kong J, Zhu X, Shi Y, et al. VDR attenuates acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system. Mol Endocrinol. 2013;27(12):2116-2125. doi:10.1210/me.2013-1146
  110. Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol 2020;92:595-601.
  111. Tomaschitz A, Pilz S, Ritz E, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta. 2010;411(17-18):1354-1360. doi:10.1016/j. cca.2010.05.037
  112. Xu J, Sriramula S, Xia H, et al. Clinical relevance and role of neuronal AT 1 receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension. Circ Res. 2017;121(1):43-55. doi:10.1161/CIRCRESAHA.116.310509
  113. Xu J, Yang J, Chen J, et al. Vitamin D alleviates lipopolysaccharide induced acute lung injury via regulation of the renin angiotensin system. Mol Med Rep. 2017;16(5):7432-7438. doi:10.3892/mmr.2017.7546
  114. Radujkovic A, Hippchen T, Tiwari-Heckler S, et al. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients. 2020;12(9):2757. doi:10.3390/nu12092757
  115. Wimalawansa SJ. Fighting against COVID-19: boosting the immunity with micronutrients, stress reduction, physical activity, and vitamin D. Nutr Food Sci. 2020;3(126):1-4.
  116. Fedson DS. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med. 2016;4(21):421. doi:10.21037/atm.2016.11.03
  117. Yuan W, Pan W, Kong J, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007;282(41):29821-29830. doi:10.1074/jbc.M705495200
  118. Wimalawansa SJ. ACE inhibitors and angiotensin receptor blockers reduce the complications associated with COVID-19 infection. World J Pharma Res. 2021;10(3):2579-2600.
  119. Entrenas castillo M, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203:105751.
  120. McGregor E, Kazemian M, Afzali B, et al. An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19; 2020. Available from: https://www.biorxiv.org/content/10.1101/2020.07.18.210161v1. Accessed November 29, 2022.
  121. McGregor TB, Sener A, Yetzer K, et al. The impact of COVID-19 on the Canadian Kidney Paired Donation program: an opportunity for universal implementation of kidney shipping. Can J Surg. 2020;63(5):E451-E453. doi:10.1503/cjs.012620
  122. Wallis G, Siracusa F, Blank M, et al. Experience of a novel community testing programme for COVID-19 in London: lessons learnt. Clin Med. 2020;20(5):e165-e169. doi:10.7861/clinmed.2020-0436
  123. Walter LA, McGregor AJ. Sex- and Gender-specific Observations and Implications for COVID-19. West J Emerg Med. 2020;21(3):507-509. doi:10.5811/westjem.2020.4.47536
  124. Stagi S. Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities? Clin Rheumatol. 2016;35(7):1865-1872. doi:10.1007/s10067-015-2970-6
  125. Kirkham FJ, Zafeiriou D, Howe D, et al. Fetal stroke and cerebrovascular disease: advances in understanding from lenticulostriate and venous imaging, alloimmune thrombocytopaenia and monochorionic twins. Eur J Paediatr Neurol. 2018;22(6):989-1005. doi:10.1016/j.ejpn.2018.08.008
  126. Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011;18(23):3506-3515. doi:10.2174/092986711796642562
  127. Hughes DA, Norton R, Aloia JF, Li-ng M. Vitamin D and respiratory health. Clin Exp Immunol 2009;158(1):20-25. doi:10.1111/j.1365- 2249.2009.04001.x
  128. Singh S, Kaur R, Singh RK. Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. Aging Clin Exp Res. 2020;32(8):1609-1612. doi:10.1007/s40520-020-01619-8
  129. Ma W, Nguyen LH, Yue Y, et al. Associations between predicted vitamin D status, vitamin D intake, and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) severity. Am J Clin Nutr. 2022;115(4):1123-1133. doi:10.1093/ajcn/nqab389
  130. D’Ecclesiis O, Gavioli C, Martinoli C, et al. Vitamin D and SARS-CoV2 infection, severity and mortality: a systematic review and meta-analysis. PLoS One. 2022;17(7):e0268396. doi:10.1371/journal.pone.0268396
  131. Chiodini I, Gatti D, Soranna D, et al. Vitamin D status and SARS-CoV-2 infection and COVID-19 clinical outcomes. Front Public Health. 2021;9:736665. doi:10.3389/fpubh.2021.736665
  132. Akbar MR, Wibowo A, Pranata R, et al. Low serum 25-hydroxyvitamin D (vitamin D) level Is associated with susceptibility to COVID-19, severity, and mortality: a systematic review and meta-analysis. Front Nutr. 2021;8:660420. doi:10.3389/fnut.2021.660420
  133. Santaolalla A, Beckmann K, Kibaru J, et al. Association between vitamin D and novel SARS-CoV-2 respiratory dysfunction - a scoping review of current evidence and its implication for COVID-19 pandemic. Front Physiol. 2020;11:564387. doi:10.3389/fphys.2020.564387
  134. Dancer RC, Parekh D, Lax S, et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax. 2015;70(7):617-624. doi:10.1136/thoraxjnl-2014-206680
  135. McCartney DM. Vitamin D and SARS-CoV-2 infection-evolution of evidence supporting clinical practice and policy development: a position statement from the Covit-D Consortium. Ir J Med Sci. 2021;190(3):1253-1265.
  136. Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020;46(2):315-328. doi:10.1007/s00134-020-05943-5
  137. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583. doi:10.1136/bmj.i6583
  138. Biesalski HK, Aggett PJ, Anton R, et al. 26th Hohenheim consensus conference, September 11, 2010 scientific substantiation of health claims: evidence-based nutrition. Nutrition. 2011;27(10 Suppl):S1-S20. doi:10.1016/j.nut.2011.04.002
  139. Tsai F, Coyle WJ. The microbiome and obesity: is obesity linked to our gut flora? Curr Gastroenterol Rep. 2009;11(4):307-313. doi:10.1007/ s11894-009-0045-z
  140. Veugelers PJ, Pham TM, Ekwaru JP. Optimal vitamin D supplementation doses that minimize the risk for both low and high serum 25-hydroxyvitamin D concentrations in the general population. Nutrients. 2015;7(12):10189-10208. doi:10.3390/nu7125527
  141. Huang Z, You T. Personalise vitamin D3 using physiologically based pharmacokinetic modelling. CPT Pharmacometrics Syst Pharmacol. 2021;10(7):723-734. doi:10.1002/psp4.12640
  142. McKenna MJ, Lyons OC, Flynn MA, et al. COVID-19 pandemic and vitamin D: rising trends in status and in daily amounts of vitamin D provided by supplements. BMJ Open. 2022;12(8):e059477. doi:10.1136/bmjopen-2021-059477
  143. Hopefl R, Ben-Eltriki M, Deb S. Association between vitamin D levels and inflammatory markers in COVID-19 patients: a meta-analysis of observational studies. JPharm Pharm Sci. 2022;25:124-136. doi:10.18433/jpps32518
  144. Rhodes JM, Subramanian S, Laird E, et al. Perspective: vitamin D deficiency and COVID-19 severity - plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2, and thrombosis (R1). J Intern Med. 2020;289:97-115. doi:10.1111/joim.13149
  145. Procter BC, Ross C, Pickard V, et al. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med. 2020;21(4):611-614.
  146. Gunn J, Hill MM, Cotten BM, et al. An analysis of biomarkers in patients with chronic pain. Pain Physician. 2020;23(1):E41-E49. doi:10.36076/ppj.2020/23/E41
  147. Chen S, Liu G, Chen J, et al. Ponatinib protects mice from lethal influenza infection by suppressing cytokine storm. Front Immunol 2019;10:1393. doi:10.3389/fimmu.2019.01393

See also: Is 50 ng of Vitamin D enough to fight COVID - TrialSiteNews - Jan 2024

There have been 7219 visits to this page

Fight infections such as COVID with 50 ng of Vitamin D – Sunil Dec 2022        
6858 visitors, last modified 31 Jan, 2024,
(Cached) Printer Friendly Follow this page for updates
Immunity 251 Virus 1382
Page actions
Refresh Print
Edit Files 6

Attached files

ID Name Comment Uploaded Size Downloads
18991 half get to 50 ng if 5,000 IU.jpg admin 16 Dec, 2022 70.12 Kb 523
18990 Risk ratio.jpg admin 16 Dec, 2022 96.71 Kb 111
18989 D vs D.jpg admin 16 Dec, 2022 70.56 Kb 429
18988 Sunil F1.jpg admin 16 Dec, 2022 77.88 Kb 426
18987 ToC Sunil.jpg admin 16 Dec, 2022 75.41 Kb 453
18986 Sunil 50 ng_CompressPdf.pdf admin 16 Dec, 2022 908.45 Kb 261